Study of a New Diagnostic Test to Guide Drug Treatment for Metastatic Colorectal Cancer Patients

What this Trial Is About

Researchers are studying a new diagnostic test called 6CAN designed to help guide treatment for patients with metastatic colorectal cancer. This test uses a cancer biopsy sample to grow patient-derived tumoroids and combines advanced machine learning and imaging techniques to find the best drug options for each patient. The study is a public-private partnership between Norwegian and Swedish organizations aiming to improve treatment outcomes, increase survivability, and reduce costs in cancer care. The study compares two groups one where the treating physician may use the 6CAN diagnostic drug screen report to guide therapy, and another receiving the standard combination treatment of trifluridinetipiracilbevacizumab in 28-day cycles. The 6CAN guided therapy may include clinically relevant on-label or off-label drugs based on drug screening of patient tumoroids. Treatment and monitoring follow each patients assigned group. Participants will undergo a biopsy to obtain tumor samples for the 6CAN test and receive treatment as per their assigned group. Researchers will monitor the success rate of obtaining usable 6CAN reports within about 6 months, along with any adverse events related to the test or study procedures. The study tracks outcomes such as therapy nominations from the test and safety data, with the total participation lasting approximately 6 months.

Evaluation of a Diagnostic Test to Identify the Best Drugs for Treatment of Metastatic Colorectal Cancer